ABSTRACT A novel induced viscosity fiber (IVF) crispy bar was formulated with the viscous dietary fibers alginate and guar gum. To evaluate the glycemic response and gastrointestinal tolerance to IVF crispy bars, nondiabetic healthy adult subjects (n ‫؍‬ 48) were studied in a randomized, double-masked, crossover design. The control crispy bars and IVF crispy bars were identical except for the 2 dietary fibers contained in the experimental (IVF) bars. After an overnight fast, subjects consumed test bars containing 50 g carbohydrate. Their capillary blood glucose response was determined for 180 min postprandially. When subjects consumed IVF, the incremental blood glucose excursions were reduced (P < 0.05) at 15, 30, 45, and 120 min. At 180 min, the subjects' blood glucose concentration was maintained above the basal blood glucose concentration for both bars. Compared with controls, the incremental peak blood glucose concentration was reduced (P < 0.001) 30% when subjects consumed IVF. When subjects consumed IVF, the positive incremental area under the curve for glucose was reduced (P < 0.01) by 33% compared with controls. In the 24-h postprandial period after each treatment, the frequency and intensity of gastrointestinal tolerance symptoms did not differ. In conclusion, compared with a control crispy bar, the IVF crispy bar attenuated the postprandial glycemic excursion without gastrointestinal intolerance in healthy adult subjects. J. Nutr. 134: 886 -889, 2004.
Because the incidence of type 2 diabetes mellitus is increasing in the population (1), there is a growing interest in therapeutic nutritional products for these individuals. The primary treatment goal is to maintain near-normal blood glucose levels. It can be challenging for busy people with diabetes mellitus to obtain convenience foods that contain the right balance of ingredients to normalize blood glucose concentrations. Therefore, individuals may choose to use a medical food to meet their dietary needs. A medical food is defined by the U.S. FDA (2) as "a food that is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."
As with any medical intervention, compliance is key to treatment success. If the medical food, no matter how effective, has poor palatability, it is unlikely to be consumed. Several food ingredients are effective at improving postprandial glycemia [e.g., guar gum (3)] and preventing nocturnal hypoglycemia [e.g., uncooked cornstarch (4)]. Unfortunately, the palatability of products containing an efficacious level of these ingredients is extremely poor. For example, foodstuffs containing viscous fibers (e.g., guar gum) usually exhibit slimy mouth-feel, tooth packing, and poor palatability (5) . The overall hedonic quality of guar-containing foods can be improved by reducing the average molecular weight (i.e., hydrolysis) of the galactomannan in guar gum (5); however, this results in a loss of clinical efficacy (6) .
As part of our research program, a search for a means to improve the palatability of medical foods that contain viscous fibers was undertaken. Two novel discoveries were made that allowed us to incorporate the soluble fibers alginate and/or guar gum into a liquid medical food. These products have a low initial viscosity, but become viscous after consumption, bringing about an improvement in the postprandial glycemic response (7) (8) (9) . Because these products have a low initial viscosity and become viscous in vivo, this technology is referred to as induced viscosity fiber (IVF).
For the present experiment, we developed an extruded starch crispy with guar gum. These high-fiber crispies were made into a bar with a strawberry layer containing the soluble fiber alginate. Because extrusion (high heat and pressure) can cause depolymerization of the fiber, which reduces the biological efficacy (6) , products developed with this technology must be clinically tested.
The primary objective of this study was to evaluate the effect of an IVF crispy bar on postprandial glycemia in nondiabetic healthy adults. The secondary objective was to evaluate the subjective gastrointestinal intolerance (i.e., nausea, abdominal cramping, distention, and flatulence) of nondiabetic healthy adults to a meal tolerance test.
SUBJECTS AND METHODS

Sensory evaluation.
A professional taste panel (Ross Products Division, Abbott Laboratories) was utilized to determine that the two crispy bars were appropriate for use in a clinical study. In addition, the two crispy bars were compared for 10 different flavor attributes, texture, and appearance, and were judged by a panel to be very similar. The IVF crispy bars exhibited good palatability, without the usual problems associated with guar gum (e.g., slimy mouth-feel and tooth packing).
Subjects. Nondiabetic, healthy subjects (n ϭ 62; 53 men, 9 women) aged 19 -75 y (mean Ϯ SEM; 44 Ϯ 2 y) were recruited. Of these, 25 failed to meet eligibility criteria and were not randomized into the study. Fourteen men withdrew from the study or were lost to follow-up after the screening visit; consequently, these subjects did not received study treatment or undergo study procedures. Thus, a total of 48 subjects were enrolled into the study. The body weight (mean Ϯ SEM) of the remaining 48 subjects was 80.8 Ϯ 1.8 kg (range ϭ 55.8 -103.3 kg). The BMI was 26.0 Ϯ 0.4 kg/m 2 (range ϭ 19.3-29.8 kg/m 2 ). Before the study, capillary blood glucose concentration was determined by finger-prick in fasting subjects. The fasting blood glucose concentration of the subjects was 4.8 Ϯ 0.10 mmol/L (range ϭ 2.7 to 5.9 mmol/L). The self-reported ethnicity of the subjects was as follows: 21 Caucasian, 18 African American, 5 Asian or Pacific Islander, 3 Latino and 1 Native American. Potential subjects were excluded from the study during an initial screening process if they had medical conditions or were taking medications (e.g., antibiotics) that would interfere with glucose metabolism or would alter the colonic bacteria. The Schulman Associates Institutional Review Board (Cincinnati, OH) reviewed and approved the experimental protocol. Informed consent was obtained from all subjects before the start of the study.
Dietary treatments. The two treatment bars evaluated in this experiment were the control crispy bar and the IVF crispy bar. These test bars consisted of a crispy base, which was slab-formed, with a strawberry paste spread on top; the entire bar was enrobed with a yogurt coating (20% of total bar weight). The crispy contained 65% corn flour, 30% soy protein, 5% maltodextrin and 35% corn flour, 30% guar gum, 30% soy protein, 5% maltodextrin for the control and experimental bars, respectively ( Table 1 ). In addition, for the experimental bar, alginate was incorporated into the strawberry paste layer. Ingredients were made into 40-g bars and individually wrapped in a foil wrapper (Nellson Nutraceutical). Subjects consumed two 40-g bars (ϳ50 g of carbohydrate) for the meal tolerance test. Subjects consumed ϳ5.5 g of guar gum and 1.6 g of sodium alginate when they took part in the IVF crispy bar meal tolerance test.
Experimental design. The study was a randomized, doublemasked, 2-period, 2-treatment, crossover design in which subjects participated in 2 separate 3-h meal tolerance tests. The tolerance tests were spaced 7 d apart for each subject. Subjects were randomly assigned to one of the 2 possible treatment sequences, and the treatments were consumed after overnight (12 h) fasting.
To ensure that subjects had similar glycogen stores on the 2 test days, they were instructed to consume a high-carbohydrate diet (minimum 150 g of carbohydrate/d) for 3 d before each meal tolerance test and were also instructed to avoid exercise 24 h before the experiment. Adequate carbohydrate intake was verified by 3-d diet records. On the evening before each meal tolerance test, all subjects consumed a low-residue dinner consisting of one 237-mL can of Ensure Plus with additional Ensure Nutrition and Energy Bars (Ross Products Division, Abbott Laboratories) to provide one third of each subject's individual daily energy requirement as estimated by the Harris-Benedict equation (10) multiplied by an activity factor of 1.3. After their low-residue evening meal, subjects were instructed to fast overnight and consume only water. Smoking was prohibited. All subjects were recruited and enrolled from one study site.
Blood glucose analysis. Capillary tubes containing sodium fluoride were used for the collection of finger-prick blood samples. A baseline sample was obtained from fasting (11-17 h) subjects after a 30-min rest. Subjects then consumed the appropriate test meal within 10 min. Finger-prick capillary blood was obtained at 15, 30, 45, 60, 90, 120, 150, and 180 min postprandially (after the start of the meal). Samples were stored at Ϫ70°C for a maximum of 3 d until analysis of whole blood glucose. Capillary blood glucose was measured by the glucose oxidase method using a YSI analyzer (YSI Model 2700 SELECT Biochemistry Analyzer, Yellow Springs Instruments).
Intolerance symptoms. Using a questionnaire, subjects were asked to report the frequency and intensity of symptoms of nausea, abdominal cramping, distention, and flatulence for the 24-h period immediately after consumption of the test bars. Intensity and frequency were set to a 10-cm line scale (0 representing "absent" and 10 "severe" and 0 representing "usual" and 10 "more than usual," respectively). Subjects placed a single perpendicular slash mark across the 10-cm horizontal line to indicate their scores for each of these variables of frequency and intensity for the 24-h period.
Calculations and statistical analysis. The positive incremental area under the curve (AUC) for glucose was calculated according to Wolever et al. (11) . Using data from a previous study (unpublished observations), a power analysis conducted before this study indicated that 42 subjects would be required to detect a 15% difference in incremental (i.e., baseline-adjusted) peak blood glucose concentration with 85% power, using an expected SD of 0.581 mmol/L. Data obtained during the 2 testing days for the blood glucose parameters were fit to a 2-period crossover model. The residuals obtained from fitting the 2-period crossover model were examined for evidence of a normal distribution with the Shapiro-Wilk test. Data were analyzed using the generalized linear model procedure in SAS (SAS version 8.2, SAS Institute), with sequence, period, and treatment effects as fixed, and subject effect as random. If the sequence effect was significant (P Ͻ 0.10), the treatment effect was analyzed using only the first period data. The symptoms of gastrointestinal tolerance were analyzed using Generalized Estimating Equations Regression (SAS). Of the 48 subjects, 44 completed the study according to protocol. Statistical results for intent-to-treat and protocol evaluable subjects were similar. Results are presented for the intent-to-treat population. P-values reported are two-sided. A result was declared to be significant when P Ͻ 0.05. 
RESULTS
The postprandial incremental blood glucose response of nondiabetic healthy adults was improved when subjects consumed IVF crispy bars compared with control crispy bars (Fig.  1) . Blood glucose concentrations of fasting subjects did not differ (P Ͼ 0.20) between treatments (3.98 Ϯ 0.12 vs. 4.08 Ϯ 0.07 mmol/L; control vs. IVF). When subjects consumed IVF, the incremental blood glucose excursions were reduced (P Ͻ 0.05) at 15, 30, 45, and 120 min. For both bars, the blood glucose concentration was maintained above the basal blood glucose concentration at 180 min.
Compared with controls, the incremental peak blood glucose concentration was reduced (P Ͻ 0.001) 30% when subjects consumed IVF (1.78 Ϯ 0.13 vs. 1.24 Ϯ 0.09 mmol/L, Table 2 ). Time to peak glucose concentration did not differ between treatments. When subjects consumed IVF, the positive incremental AUC was reduced (P Ͻ 0.01) by 33% compared with control [90 Ϯ 10 vs. 134 Ϯ 14 (mmol ⅐ min)/L].
In the 24-h postprandial period (0 -24 h), the frequency and intensity of gastrointestinal tolerance symptoms (nausea, abdominal cramping, distention, and flatulence) did not differ after each of the treatments. Overall, the ratings of the symptoms were low and of little physiologic importance. One adverse event was documented for a subject with symptoms of diarrhea and heartburn after consuming the control crispy bar.
DISCUSSION
In light of the Institute of Medicine's Food and Nutrition Board proposed definition of dietary fiber (12), additional research is required to more accurately evaluate the physiologic effects of functional fiber. The Food and Nutrition Board has recommended the elimination of the soluble/insoluble fiber terminology and the addition of more functional physiochemical properties such as viscosity and fermentability. The present experiment was conducted to evaluate the effects of purified viscous dietary fiber (functional fiber) on postprandial glycemia in nondiabetic, healthy adult subjects.
Alginate is the sodium salt of alginic acid and is isolated from brown seaweed (13) . It is composed of mannuronic and guluronic acids, which can react with free ions such as calcium, forming a viscous solution (13) . In a medical nutritional product, the formation of viscosity depends upon the release of calcium ions, which has been shown to improve postprandial glycemia in healthy subjects (7) . Guar gum is a galactomannan isolated from the endosperm of the seeds of the Indian cluster bean (Cyamposis tetragonolobus), a leguminous vegetable. It is composed of a ␤-1,4 mannose backbone with galactose side chains linked ␣-1,6. Certain protein sources or low dextroseequivalent maltodextrins can prevent the dissolution of neutral polymers such as guar gum (unpublished information). This viscous fiber was added to a liquid carbohydrate-based beverage with a low initial viscosity and was found to improve postprandial glycemia in healthy adults (8) . It is upon ingestion that salivary amylase would hydrolyze the maltodextrin, allowing the fiber to solubilize and form a viscous chyme.
In the present experiment, these novel IVF concepts were adapted to a nutritional bar, and its effect upon postprandial glycemia and symptoms of gastrointestinal tolerance in nondiabetic healthy adult subjects was evaluated. This study demonstrated that subjects consuming IVF had an attenuated postprandial glycemic response compared with subjects consuming the control crispy bar.
Alginate or guar gum supplementation to a meal tolerance test has been shown to improve postprandial glycemia (3,14 -17) . However, poor palatability (5) and gastrointestinal intolerance have limited its acceptability and clinical use. Novel methods to incorporate viscous dietary fibers into a palatable nutritional product are warranted so that nutritional intervention can play a primary role in adjunctive therapy for individuals with diabetes mellitus. Sensory evaluation by a professional panel (Ross Products Division) of our IVF crispy bar found it to be similar in taste, texture, and appearance to the control crispy bar without any added fiber. In addition, we found that the rating of symptoms of gastrointestinal intolerance was similar between the products when subjects consumed two 40-g bars as a meal tolerance test.
In summary, IVF crispy bars in comparison with control crispy bars reduce the glycemic excursion, maintain blood glucose concentrations above baseline over a prolonged period (at least to 180 min), and are well tolerated in nondiabetic, healthy subjects. Induced viscosity fiber crispy bars help maintain blood glucose levels by reducing the early phase excursion and by appropriately maintaining the later phase excursion. In theory, the induction of viscosity delays gastric emptying and possibly nutrient absorption in the small intestine. Further 
FIGURE 1
Incremental change from baseline in capillary blood glucose response for subjects consuming 50 g of carbohydrate from control or IVF crispy bars in a crossover design. Blood glucose concentrations of fasting subjects did not differ (3.98 Ϯ 0.12 vs. 4.08 Ϯ 0.07 mmol/L; control vs. IVF). Values are means Ϯ SEM, n ϭ 45-48. Time points with asterisks indicate significant differences between means, *P Ͻ 0.05, **P Ͻ 0.01.
investigation of the possible beneficial effects of IVF crispy bars in individuals with diabetes mellitus is recommended.
